Insight Molecular Diagnostics Inc.(IMDX)Earnings, Financials & Key Ratios
IMDX•NASDAQ
$5.03
$88M mkt cap·Price updated May 6, 2026
AboutOncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Show more
- Revenue$2M+25.1%
- EBITDA-$59M-153.6%
- Net Income-$61M-118.4%
- EPS (Diluted)-4.66-24.3%
- Gross Margin39.34%+43.2%
- EBITDA Margin-3161.99%-102.6%
- Operating Margin-3245.14%-94.0%
- Net Margin-3225.04%-74.5%
- ROE-1480.67%-1500.6%
- Interest Coverage-726.68-50.3%
IMDX Key Insights
Insight Molecular Diagnostics Inc. (IMDX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 70.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
IMDX Price & Volume
Insight Molecular Diagnostics Inc. (IMDX) stock price & volume — 10-year historical chart
Loading chart...
IMDX Growth Metrics
Insight Molecular Diagnostics Inc. (IMDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-5.06%
TTM520.87%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-40.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM36.08%
Return on Capital
10 Years-126.14%
5 Years-60.83%
3 Years-58.51%
Last Year-127.83%
IMDX Recent Earnings
Insight Molecular Diagnostics Inc. (IMDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (55%)
Q4 2025Latest
Nov 10, 2025EPS
$0.34
Est $0.24
-41.7%
Revenue
$260,000
Est $285,000
-8.8%
Q3 2025
Aug 11, 2025EPS
$0.30
Est $0.23
-30.4%
Revenue
$518,000
Est $300,000
+72.7%
Q2 2025
May 12, 2025EPS
$0.26
Est $0.24
-8.3%
Revenue
$2M
Est $126,780
+1586.4%
Q2 2025
Mar 24, 2025EPS
$0.48
Est $0.43
+211.6%
Revenue
$1M
Est $158,550
+837.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 10, 2025 | $0.34vs $0.24-41.7% | $260,000vs $285,000-8.8% |
| Q3 2025 | Aug 11, 2025 | $0.30vs $0.23-30.4% | $518,000vs $300,000+72.7% |
| Q2 2025 | May 12, 2025 | $0.26vs $0.24-8.3% | $2Mvs $126,780+1586.4% |
| Q2 2025 | Mar 24, 2025 | $0.48vs $0.43+211.6% | $1Mvs $158,550+837.2% |
Based on last 12 quarters of dataView full earnings history →
IMDX Peer Comparison
Insight Molecular Diagnostics Inc. (IMDX) competitors in Diagnostics and Omics Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 CDNA | 1.08B | 20.94 | -52.35 | 13.79% | -1.98% | -2.61% | 0.06 | |
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 | |
 PACB | 516.17M | 1.71 | -1.60 | -23.19% | -325.8% | -13.95% | 1.33 | |
 FLGT | 443.83M | 14.92 | -7.57 | 13.83% | -18.75% | -5.42% | 0.00 | |
 MYRG | 7.08B | 454.78 | 60.40 | 8.79% | 3.71% | 22.14% | 0.16 | |
 TMO | 175.76B | 472.95 | 26.66 | 3.91% | 15.18% | 13.23% | 0.76 |
Compare IMDX vs Peers
Insight Molecular Diagnostics Inc. (IMDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMDX Income Statement
Insight Molecular Diagnostics Inc. (IMDX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 1.22M | 2.2M | 958K | 1.5M | 1.88M | 4.4M |
| Revenue Growth % | - | - | - | - | - | 80.76% | -56.41% | 56.89% | 25.15% | 520.87% |
| Cost of Goods Sold | 387K | 580K | 559K | 344K | 1.85M | 778K | 976K | 1.09M | 1.14M | 1.99M |
| COGS % of Revenue | - | - | - | - | 152.55% | 35.4% | 101.88% | 72.52% | 60.66% | - |
| Gross Profit | -387K▲ 0% | -580K▼ 49.9% | -559K▲ 3.6% | -344K▲ 38.5% | -639K▼ 85.8% | 1.42M▲ 322.2% | -18K▼ 101.3% | 413K▲ 2394.4% | 740K▲ 79.2% | 2.41M▲ 0% |
| Gross Margin % | - | - | - | - | -52.55% | 64.6% | -1.88% | 27.48% | 39.34% | 54.73% |
| Gross Profit Growth % | -36.75% | -49.87% | 3.62% | 38.46% | -85.76% | 322.22% | -101.27% | 2394.44% | 79.18% | - |
| Operating Expenses | 11.14M | 18.85M | 15.2M | 22.24M | 29.07M | 55.15M | 17.98M | 25.55M | 61.78M | 63.73M |
| OpEx % of Revenue | - | - | - | - | 2390.79% | 2508.87% | 1876.72% | 1699.87% | 3284.48% | - |
| Selling, General & Admin | 5.46M | 11.68M | 8.69M | 15.45M | 23.28M | 20.39M | 21.53M | 13.29M | 13.79M | 15.76M |
| SG&A % of Revenue | - | - | - | - | 1914.64% | 927.75% | 2247.7% | 883.9% | 732.85% | - |
| Research & Development | 5.68M | 7.17M | 6.51M | 6.79M | 9.8M | 5.04M | 7.3M | 9.29M | 9.84M | 12.34M |
| R&D % of Revenue | - | - | - | - | 805.92% | 229.07% | 762.11% | 618.36% | 523.07% | - |
| Other Operating Expenses | 0 | 0 | 91K | 0 | -4.01M | 29.72M | -10.86M | 2.97M | 38.16M | 3.88M |
| Operating Income | -11.14M▲ 0% | -18.85M▼ 69.2% | -15.2M▲ 19.3% | -22.24M▼ 46.3% | -29.71M▼ 33.6% | -53.73M▼ 80.8% | -18M▲ 66.5% | -25.14M▼ 39.7% | -61.04M▼ 142.8% | -61.32M▲ 0% |
| Operating Margin % | - | - | - | - | -2443.34% | -2444.27% | -1878.6% | -1672.39% | -3245.14% | -1392.91% |
| Operating Income Growth % | -27.78% | -69.2% | 19.35% | -46.29% | -33.6% | -80.83% | 66.5% | -39.67% | -142.84% | - |
| EBITDA | -10.75M | -18.27M | -14.64M | -21.89M | -29.32M | -49.52M | -12.78M | -23.46M | -59.48M | -59.12M |
| EBITDA Margin % | - | - | - | - | -2410.94% | -2252.96% | -1333.72% | -1560.61% | -3161.99% | -1343% |
| EBITDA Growth % | -27.48% | -69.9% | 19.85% | -49.53% | -33.9% | -68.91% | 74.2% | -83.58% | -153.57% | -39.87% |
| D&A (Non-Cash Add-back) | 387K | 580K | 559K | 344K | 394K | 4.21M | 5.22M | 1.68M | 1.56M | 2.2M |
| EBIT | -11.14M | -18.85M | -15.54M | -22.24M | -30.93M | -52.66M | -18.53M | -24.8M | -60.58M | -60.66M |
| Net Interest Income | 0 | 0 | 0 | 0 | -252K | -209K | -83K | -52K | -84K | -113K |
| Interest Income | 0 | 0 | 0 | 299K | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 28K | 217K | 216K | 299K | 252K | 209K | 83K | 52K | 84K | 113K |
| Other Income/Expense | -28K | -526K | -552K | -187K | -1.48M | 854K | -615K | 281K | 378K | 538K |
| Pretax Income | -11.17M▲ 0% | -19.38M▼ 73.5% | -15.75M▲ 18.7% | -22.43M▼ 42.4% | -31.19M▼ 39.1% | -52.87M▼ 69.5% | -18.61M▲ 64.8% | -24.86M▼ 33.5% | -60.66M▼ 144.1% | -60.78M▲ 0% |
| Pretax Margin % | - | - | - | - | -2564.64% | -2405.41% | -1942.8% | -1653.69% | -3225.04% | -1380.69% |
| Income Tax | 0 | 0 | 0 | 0 | -1.25M | -9.26M | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 4.02% | 17.52% | 0% | 0% | 0% | 0% |
| Net Income | -11.17M▲ 0% | -19.38M▼ 73.5% | -15.75M▲ 18.7% | -22.33M▼ 41.7% | -29.93M▼ 34.0% | -64.1M▼ 114.1% | -72.9M▼ 13.7% | -27.78M▲ 61.9% | -60.66M▼ 118.4% | -60.78M▲ 0% |
| Net Margin % | - | - | - | - | -2461.51% | -2916.15% | -7609.81% | -1848.37% | -3225.04% | -1380.69% |
| Net Income Growth % | -27.85% | -73.49% | 18.69% | -41.74% | -34.05% | -114.14% | -13.74% | 61.89% | -118.36% | -40.87% |
| Net Income (Continuing) | -11.17M | -19.38M | -15.75M | -22.43M | -29.93M | -43.61M | -18.61M | -24.86M | -60.66M | -60.78M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | -20.49M | -54.29M | -2.93M | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -8.42▲ 0% | -12.83▼ 52.4% | -8.32▲ 35.2% | -8.71▼ 4.7% | -9.14▼ 4.9% | -14.40▼ 57.5% | -20.00▼ 38.9% | -3.75▲ 81.3% | -4.66▼ 24.3% | -1.90▲ 0% |
| EPS Growth % | -1.2% | -52.38% | 35.15% | -4.69% | -4.94% | -57.55% | -38.89% | 81.25% | -24.3% | 36.08% |
| EPS (Basic) | -8.42 | -12.83 | -8.32 | -8.71 | -9.14 | -14.40 | -20.00 | -3.75 | -4.66 | - |
| Diluted Shares Outstanding | 1.33M | 1.51M | 1.89M | 2.56M | 3.27M | 4.45M | 5.54M | 7.65M | 13.07M | 32.03M |
| Basic Shares Outstanding | 1.33M | 1.51M | 1.89M | 2.56M | 3.27M | 4.45M | 5.54M | 7.65M | 13.07M | 32.03M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
IMDX Balance Sheet
Insight Molecular Diagnostics Inc. (IMDX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 12.7M | 8.53M | 8.64M | 22.96M | 9.23M | 39.14M | 25.54M | 10.7M | 11.76M | 21.39M |
| Cash & Short-Term Investments | 12.41M | 8.36M | 8.46M | 22.45M | 7.82M | 33.85M | 20.43M | 9.43M | 8.64M | 18.69M |
| Cash Only | 10.17M | 7.6M | 8.03M | 22.07M | 7.14M | 32.95M | 19.99M | 9.43M | 8.64M | 18.69M |
| Short-Term Investments | 2.24M | 760K | 428K | 379K | 675K | 904K | 433K | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 203K | 1.44M | 2.01M | 484K | 1.61M | 258K |
| Days Sales Outstanding | - | - | - | - | 60.93 | 238.63 | 766.58 | 117.54 | 313 | 122.78 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 304K | 0 | 0 | 410K | 471K |
| Days Inventory Outstanding | - | - | - | - | - | 142.62 | - | - | 131.16 | 93.08 |
| Other Current Assets | 285K | 168K | 180K | 425K | 941K | 2.94M | 2.12M | 782K | 1.1M | 1.97M |
| Total Non-Current Assets | 1.75M | 1.69M | 876K | 16.9M | 46.19M | 120.42M | 74.56M | 64.19M | 23.32M | 22.55M |
| Property, Plant & Equipment | 688K | 822K | 614K | 3.73M | 6.52M | 8.37M | 10.85M | 5.44M | 2.76M | 2.34M |
| Fixed Asset Turnover | - | - | - | - | 0.19x | 0.26x | 0.09x | 0.28x | 0.68x | 1.19x |
| Goodwill | 0 | 0 | 0 | 0 | 9.19M | 18.68M | 0 | 0 | 0 | 0 |
| Intangible Assets | 988K | 746K | 0 | 0 | 15.01M | 61.72M | 61.63M | 56.59M | 14.61M | 14.6M |
| Long-Term Investments | 0 | 0 | 0 | 10.96M | 13.42M | 0 | 0 | 0 | 1.7M | 5.1M |
| Other Non-Current Assets | 75K | 120K | 262K | 2.21M | 1.94M | 31.65M | 2.07M | 2.16M | 4.26M | 15.36M |
| Total Assets | 14.45M▲ 0% | 10.22M▼ 29.3% | 9.52M▼ 6.8% | 39.86M▲ 318.8% | 55.42M▲ 39.0% | 159.56M▲ 187.9% | 100.09M▼ 37.3% | 74.89M▼ 25.2% | 35.08M▼ 53.2% | 43.94M▲ 0% |
| Asset Turnover | - | - | - | - | 0.02x | 0.01x | 0.01x | 0.02x | 0.05x | 0.09x |
| Asset Growth % | 13.48% | -29.29% | -6.83% | 318.77% | 39.04% | 187.92% | -37.27% | -25.18% | -53.16% | -137.93% |
| Total Current Liabilities | 4.28M | 4.45M | 5.56M | 4.44M | 9M | 14.12M | 12.11M | 7.19M | 7.28M | 7.66M |
| Accounts Payable | 422K | 175K | 166K | 469K | 432K | 1.81M | 1.25M | 953K | 2.28M | 1.06M |
| Days Payables Outstanding | 398.01 | 110.13 | 108.39 | 497.63 | 85 | 849.16 | 468.59 | 319.12 | 729.04 | 315.51 |
| Short-Term Debt | 202K | 1.14M | 1.19M | 1.35M | 2.39M | 1.31M | 0 | 0 | 0 | 1.6M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 46K | 2.4M | 3.02M | 1.09M | 0 | 6.71M | 4.43M | 4.01M | 2.17M | 5.01M |
| Current Ratio | 2.97x | 1.91x | 1.55x | 5.17x | 1.03x | 2.77x | 2.11x | 1.49x | 1.62x | 1.62x |
| Quick Ratio | 2.97x | 1.91x | 1.55x | 5.17x | 1.03x | 2.75x | 2.11x | 1.49x | 1.56x | 1.56x |
| Cash Conversion Cycle | - | - | - | - | - | -467.91 | - | - | -284.89 | -99.65 |
| Total Non-Current Liabilities | 310K | 1.36M | 534K | 4.58M | 12.94M | 80.23M | 48.39M | 47.23M | 40.08M | 45.47M |
| Long-Term Debt | 0 | 1.07M | 347K | 1.91M | 1.51M | 0 | 0 | 0 | 0 | 1.53M |
| Capital Lease Obligations | 310K | 289K | 187K | 2.68M | 4.31M | 3.54M | 2.73M | 2.2M | 2.37M | 6.28M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 7.12M | 76.68M | 45.66M | 45.03M | 37.71M | 160.97M |
| Total Liabilities | 4.58M | 5.81M | 6.09M | 9.02M | 21.94M | 94.35M | 60.5M | 54.42M | 47.35M | 53.13M |
| Total Debt | 512K | 2.5M | 1.72M | 6.17M | 8.63M | 5.68M | 3.54M | 2.87M | 3.66M | 3.13M |
| Net Debt | -9.66M | -5.1M | -6.32M | -15.91M | 1.49M | -27.27M | -16.45M | -6.56M | -4.97M | -15.56M |
| Debt / Equity | 0.05x | 0.57x | 0.50x | 0.20x | 0.26x | 0.09x | 0.09x | 0.14x | - | -0.34x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.05x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.26x |
| Interest Coverage | -397.86x | -86.86x | -70.38x | -74.38x | -117.90x | -257.06x | -216.83x | -483.38x | -726.68x | -536.86x |
| Total Equity | 9.86M▲ 0% | 4.4M▼ 55.4% | 3.42M▼ 22.3% | 30.84M▲ 800.9% | 33.48M▲ 8.6% | 65.22M▲ 94.8% | 39.59M▼ 39.3% | 20.47M▼ 48.3% | -12.27M▼ 160.0% | -9.2M▲ 0% |
| Equity Growth % | -5.33% | -55.35% | -22.26% | 800.91% | 8.58% | 94.78% | -39.29% | -48.31% | -159.97% | -489.44% |
| Book Value per Share | 7.43 | 2.92 | 1.81 | 12.02 | 10.23 | 14.67 | 7.15 | 2.68 | -0.94 | -0.29 |
| Total Shareholders' Equity | 9.86M | 4.4M | 3.42M | 30.84M | 33.48M | 65.22M | 39.59M | 20.47M | -12.27M | -9.2M |
| Common Stock | 45.82M | 59.97M | 74.74M | 124.58M | 157.16M | 252.95M | 294.93M | 310.3M | 338.24M | 368.52M |
| Retained Earnings | -35.3M | -54.68M | -71.32M | -93.75M | -123.68M | -187.77M | -260.68M | -289.88M | -350.54M | -377.81M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -654K | -888K | 0 | 0 | 0 | 37K | 39K | 49K | 21K | 86K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMDX Cash Flow Statement
Insight Molecular Diagnostics Inc. (IMDX) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -7.52M | -13.38M | -11.65M | -19.71M | -25.98M | -35.94M | -45.57M | -23.32M | -20.71M | -20.71M |
| Operating CF Margin % | - | - | - | - | -2136.51% | -1635.17% | -4756.58% | -1551.9% | -1101.17% | - |
| Operating CF Growth % | -77.87% | -77.94% | 12.97% | -69.24% | -31.78% | -38.34% | -26.79% | 48.81% | 11.2% | -56.45% |
| Net Income | -11.17M | -19.38M | -15.75M | -22.43M | -29.93M | -64.1M | -72.9M | -27.78M | -60.66M | -60.78M |
| Depreciation & Amortization | 387K | 580K | 559K | 351K | 394K | 4.21M | 5.22M | 1.68M | 1.56M | 2.2M |
| Stock-Based Compensation | 922K | 1.63M | 1.48M | 3M | 5.07M | 6.84M | 10.04M | 6.57M | 1.91M | 1.54M |
| Deferred Taxes | 0 | 4.38M | 956K | 483K | -1.25M | -9.26M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.7M | 83K | 118K | 437K | -2.24M | 26.22M | 14.01M | 174K | 37.79M | 37.24M |
| Working Capital Changes | 2.34M | -686K | 993K | -1.55M | 1.98M | 149K | -1.94M | -3.97M | -1.32M | -2.2M |
| Change in Receivables | 0 | 0 | 0 | 0 | -182K | -1.23M | -575K | 109K | -1.13M | -49K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -410K | -239K |
| Change in Payables | 229K | -48K | 1M | 741K | 848K | -1.35M | 297K | -4.76M | 967K | -1.38M |
| Cash from Investing | -181K | 843K | -31K | -12.41M | -11.75M | -13.96M | -4.34M | -932K | -512K | -1.92M |
| Capital Expenditures | -106K | -91K | -31K | -918K | -1.23M | -2.25M | -4.34M | -281K | -516K | -1.92M |
| CapEx % of Revenue | - | - | - | - | 100.9% | 102.23% | 453.03% | 18.7% | 27.43% | - |
| Acquisitions | 0 | 0 | 0 | -11.24M | -10.51M | -11.71M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -75K | 934K | -240K | -252K | -7K | 0 | 0 | -1.02M | 4K | 4K |
| Cash from Financing | 9.88M | 9.97M | 12.11M | 47.87M | 22.8M | 78.36M | 35.81M | 12.19M | 20.43M | 39.16M |
| Debt Issued (Net) | -114K | 1.58M | -1.18M | 1.36M | 695K | -1.53M | -1.43M | -117K | -201K | -414K |
| Equity Issued (Net) | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 2M |
| Dividends Paid | 0 | 0 | -96K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -14K | -239K | 0 | 0 | 0 | 0 |
| Other Financing | -555K | 8.38M | -201K | 0 | 1.31M | 2.15M | -483K | -427K | -1.79M | -1.56M |
| Net Change in Cash | 2.18M▲ 0% | -2.57M▼ 218.2% | 434K▲ 116.9% | 15.74M▲ 3526.3% | -14.93M▼ 194.9% | 28.46M▲ 290.6% | -14.1M▼ 149.5% | -12.07M▲ 14.4% | -796K▲ 93.4% | 15.15M▲ 0% |
| Free Cash Flow | -7.63M▲ 0% | -13.48M▼ 76.7% | -11.68M▲ 13.3% | -20.63M▼ 76.7% | -27.21M▼ 31.9% | -38.19M▼ 40.4% | -49.91M▼ 30.7% | -23.61M▲ 52.7% | -21.23M▲ 10.1% | -23.91M▲ 0% |
| FCF Margin % | - | - | - | - | -2237.42% | -1737.4% | -5209.6% | -1570.59% | -1128.6% | -543.23% |
| FCF Growth % | -61.3% | -76.66% | 13.33% | -76.65% | -31.86% | -40.36% | -30.69% | 52.7% | 10.07% | -18.47% |
| FCF per Share | -5.75 | -8.93 | -6.17 | -8.04 | -8.31 | -8.59 | -9.01 | -3.09 | -1.62 | -1.62 |
| FCF Conversion (FCF/Net Income) | 0.67x | 0.69x | 0.74x | 0.88x | 0.87x | 0.56x | 0.63x | 0.84x | 0.34x | 0.39x |
| Interest Paid | 0 | 0 | 0 | 0 | 209K | 114K | 0 | 0 | 0 | 49K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMDX Key Ratios
Insight Molecular Diagnostics Inc. (IMDX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -110.14% | -271.64% | -402.61% | -130.35% | -93.07% | -129.88% | -139.11% | -92.51% | -1480.67% | 2394.25% |
| Return on Invested Capital (ROIC) | -637.54% | - | - | -277.06% | -89.3% | -110.52% | -44.19% | -101.77% | - | 232.39% |
| Gross Margin | - | - | - | - | -52.55% | 64.6% | -1.88% | 27.48% | 39.34% | 54.73% |
| Net Margin | - | - | - | - | -2461.51% | -2916.15% | -7609.81% | -1848.37% | -3225.04% | -1380.69% |
| Debt / Equity | 0.05x | 0.57x | 0.50x | 0.20x | 0.26x | 0.09x | 0.09x | 0.14x | - | -0.34x |
| Interest Coverage | -397.86x | -86.86x | -70.38x | -74.38x | -117.90x | -257.06x | -216.83x | -483.38x | -726.68x | -536.86x |
| FCF Conversion | 0.67x | 0.69x | 0.74x | 0.88x | 0.87x | 0.56x | 0.63x | 0.84x | 0.34x | 0.39x |
| Revenue Growth | - | - | - | - | - | 80.76% | -56.41% | 56.89% | 25.15% | 520.87% |
IMDX Frequently Asked Questions
Insight Molecular Diagnostics Inc. (IMDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Insight Molecular Diagnostics Inc. (IMDX) reported $4.4M in revenue for fiscal year 2024.
Insight Molecular Diagnostics Inc. (IMDX) grew revenue by 25.1% over the past year. This is strong growth.
Insight Molecular Diagnostics Inc. (IMDX) reported a net loss of $60.8M for fiscal year 2024.
Dividend & Returns
Insight Molecular Diagnostics Inc. (IMDX) has a return on equity (ROE) of -1480.7%. Negative ROE indicates the company is unprofitable.
Insight Molecular Diagnostics Inc. (IMDX) had negative free cash flow of $23.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More IMDX
Insight Molecular Diagnostics Inc. (IMDX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates